A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.
Phase 2 – studying effectiveness and dosage
Conditions:
Non-segmental vitiligo
Sponsor: Takeda Development Center Americas Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24
Proportion of participants achieving ≥75% improvement from baseline in F-VASI at Week 24.
Description
Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 144 participants
Interventions
ZASOCITINIB
Drug
ZASOCITINIB
Drug
White opaque, hard hypromellose capsule, size 3 containing same excipients as TAK-279 active capsule
БГ